The Chronic Pruritus Market is making significant strides, fueled by innovative treatment approaches and ongoing research ...

53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ARCADIA clinical trial programs, showing that Nemluvio has the potential to address the ...

Larry Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children's Hospital, presented a session at ...

Please provide your email address to receive an email when new articles are posted on . Nemluvio’s approved indications include atopic dermatitis in patients aged 12 years and older and prurigo ...

Galderma has won approval from the European Commission (EC) for subcutaneous injection Nemluvio (nemolizumab) for the treatment of atopic dermatitis (AD), becoming the latest pharmaceutical ...

Investing.com -- Galderma Group AG has been downgraded by RBC Capital Markets to "sector perform" from "outperform," ...

The stock dropped after the skincare company warned that it expects investments in a dermatological drug to hit profitability ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...

(BUSINESS WIRE )--Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU).